Profile data is unavailable for this security.
About the company
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
- Revenue in USD (TTM)573.35m
- Net income in USD69.50m
- Incorporated2021
- Employees1.01k
- LocationAlvotech SA9, Rue De BitbourgLUXEMBOURG 1273LuxembourgLUX
- Websitehttps://www.alvotech.com/
More ▼
Mergers & acquisitions
| Acquired company | ALVO:NMQ since announced | Transaction value |
|---|---|---|
| Xbrane Biopharma Ab-R&D Operations | -59.08% | 27.25m |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.33bn | 69.00 | -- | 2.60 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.33bn | 26.00 | -- | 7.03 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.35bn | 123.00 | -- | 49.37 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.37bn | 403.00 | -- | 1.84 | -- | 23.90 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Novavax Inc | 1.06bn | 341.75m | 1.41bn | 952.00 | 4.84 | -- | 3.75 | 1.33 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.42bn | 130.00 | -- | 5.67 | -- | 94.48 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.45bn | 1.01k | 22.17 | -- | 13.76 | 2.52 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Nektar Therapeutics | 62.60m | -120.74m | 1.45bn | 61.00 | -- | 16.48 | -- | 23.18 | -7.93 | -7.93 | 4.10 | 4.33 | 0.2055 | -- | 97.13 | 1,026,230.00 | -37.21 | -35.30 | -47.69 | -39.56 | 87.26 | 75.63 | -181.08 | -323.39 | -- | -8.54 | 0.469 | -- | 9.22 | -3.00 | 56.91 | -- | -43.84 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.47bn | 136.00 | -- | -- | -- | 8.67 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.49bn | 60.00 | -- | 5.32 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.51bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.53bn | 186.00 | -- | 2.55 | -- | 587.82 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| Relay Therapeutics Inc | 8.36m | -297.59m | 1.55bn | 188.00 | -- | 2.54 | -- | 185.23 | -1.75 | -1.75 | 0.0491 | 3.52 | 0.0104 | -- | -- | 32,015.33 | -37.20 | -31.62 | -39.14 | -32.85 | -- | -- | -3,561.43 | -1,130.74 | -- | -- | 0.00 | -- | -60.83 | -- | 1.25 | -- | -24.08 | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.55bn | 123.00 | -- | 4.67 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.55bn | 74.00 | -- | 9.26 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.56bn | 28.00 | -- | 3.22 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
Data as of Feb 13 2026. Currency figures normalised to Alvotech SA's reporting currency: US Dollar USD
4.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.39m | 1.16% |
| Bracebridge Capital LLCas of 30 Sep 2025 | 2.71m | 0.93% |
| Oaktree Capital Management LPas of 30 Sep 2025 | 1.56m | 0.54% |
| T. Rowe Price International Ltd.as of 30 Sep 2025 | 1.45m | 0.50% |
| Littlejohn & Co. LLC (Investment Management)as of 30 Sep 2025 | 1.32m | 0.45% |
| PointState Capital LPas of 30 Sep 2025 | 1.05m | 0.36% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 948.32k | 0.33% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 627.64k | 0.22% |
| Legal & General Investment Management Ltd.as of 30 Sep 2025 | 526.87k | 0.18% |
| Landsbr�f hfas of 09 Jan 2026 | 348.15k | 0.12% |
More ▼
Data from 30 Sep 2025 - 09 Jan 2026Source: FactSet Research Systems Inc.
